Aldeyra Therapeutics Stock Forecast
NASDAQ: ALDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ALDX analyst consensus
Consensus (6 analysts)
strong_buy
Avg. price target
$6.60+596.42%
- Strong buy 1
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering Aldeyra Therapeutics (2026-10-09), 5 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $6.60, with a high estimate of $13.00 and a low estimate of $2.00. The average target implies upside of 596.4% from the current price of $0.9477.
The spread between the highest and lowest targets is 550.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ALDX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 17% |
| Buy | 4 | 67% |
| Hold | 1 | 17% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $2.00 | +111.04% |
| Average target | $6.60 | +596.42% |
| High target | $13.00 | +1271.74% |